QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:AKRO

Akero Therapeutics (AKRO) Stock Forecast, Price & News

$45.36
-0.56 (-1.22%)
(As of 09/25/2023 ET)
Compare
Today's Range
$44.95
$45.94
50-Day Range
$41.19
$52.25
52-Week Range
$25.97
$58.38
Volume
684,317 shs
Average Volume
678,985 shs
Market Capitalization
$2.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.86

Akero Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
45.2% Upside
$65.86 Price Target
Short Interest
Bearish
11.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.43mentions of Akero Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Acquiring Shares
$3.41 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.70) to ($3.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

548th out of 961 stocks

Pharmaceutical Preparations Industry

250th out of 454 stocks


AKRO stock logo

About Akero Therapeutics (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Price History

AKRO Stock News Headlines

LifeSci Capital Remains a Buy on Akero Therapeutics (AKRO)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
4 Analysts Have This to Say About Akero Therapeutics
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Akero Gains on Buy Rating, Test Results
Akero Therapeutics: An Assessment
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Company Calendar

Last Earnings
8/11/2023
Today
9/25/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.86
High Stock Price Forecast
$83.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+45.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-112,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.98 per share

Miscellaneous

Free Float
50,214,000
Market Cap
$2.52 billion
Optionable
Not Optionable
Beta
-0.94
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Andrew Cheng M.D. (Age 56)
    Ph.D., Pres, CEO & Director
    Comp: $1.22M
  • Dr. Jonathan M. Young J.D. (Age 53)
    Ph.D., Co-Founder, Exec. VP, COO & Sec.
    Comp: $763.3k
  • Dr. Timothy Rolph (Age 69)
    Co-Founder & Chief Scientific Officer
    Comp: $819.4k
  • Mr. William R. White J.D. (Age 50)
    Exec. VP, CFO, Treasurer & Head of Corp. Devel.
    Comp: $768.4k
  • Ms. Catriona  YaleMs. Catriona Yale (Age 51)
    Exec. VP & Chief Devel. Officer
    Comp: $754.8k
  • Mr. Patrick Lamy (Age 50)
    Sr. VP of Commercial Strategy
  • Mr. John J. Schembri (Age 61)
    VP of Fin. & Controller













AKRO Stock - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price forecast for 2023?

8 Wall Street analysts have issued 12 month price objectives for Akero Therapeutics' stock. Their AKRO share price forecasts range from $58.00 to $83.00. On average, they anticipate the company's share price to reach $65.86 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2023?

Akero Therapeutics' stock was trading at $54.80 on January 1st, 2023. Since then, AKRO stock has decreased by 17.2% and is now trading at $45.36.
View the best growth stocks for 2023 here
.

Are investors shorting Akero Therapeutics?

Akero Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,330,000 shares, an increase of 8.0% from the August 15th total of 5,860,000 shares. Based on an average daily trading volume, of 678,200 shares, the short-interest ratio is presently 9.3 days.
View Akero Therapeutics' Short Interest
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Friday, August, 11th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.01.

What ETFs hold Akero Therapeutics' stock?
What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.63%), State Street Corp (4.47%), Perceptive Advisors LLC (3.49%), General Atlantic L.P. (3.56%), Boxer Capital LLC (3.35%) and Commodore Capital LP (3.34%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $45.36.

How much money does Akero Therapeutics make?

Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $2.52 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com.

This page (NASDAQ:AKRO) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -